BG104059A - Diabetes treatment with rosiglytazone and insulin - Google Patents
Diabetes treatment with rosiglytazone and insulinInfo
- Publication number
- BG104059A BG104059A BG104059A BG10405900A BG104059A BG 104059 A BG104059 A BG 104059A BG 104059 A BG104059 A BG 104059A BG 10405900 A BG10405900 A BG 10405900A BG 104059 A BG104059 A BG 104059A
- Authority
- BG
- Bulgaria
- Prior art keywords
- rosiglytazone
- insulin
- diabetes treatment
- treatment
- nontoxic
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 4
- 102000004877 Insulin Human genes 0.000 title abstract 2
- 108090001061 Insulin Proteins 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 229940125396 insulin Drugs 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712866.4A GB9712866D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
| PCT/EP1998/003692 WO1998057636A1 (en) | 1997-06-18 | 1998-06-15 | Treatment of diabetes with rosiglitazone and insulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG104059A true BG104059A (en) | 2000-10-31 |
Family
ID=10814527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104059A BG104059A (en) | 1997-06-18 | 2000-01-06 | Diabetes treatment with rosiglytazone and insulin |
Country Status (30)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| PL351686A1 (en) | 1999-04-23 | 2003-06-02 | Smithkline Beecham Plc | Novel pharmaceutical |
| US6660716B1 (en) | 1999-06-21 | 2003-12-09 | Eli Lilly And Company | Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof |
| WO2001000223A2 (en) | 1999-06-25 | 2001-01-04 | Minimed Inc. | Multiple agent diabetes therapy |
| US6468507B1 (en) * | 2000-05-01 | 2002-10-22 | Aeropharm Technology, Inc. | Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
| GB0023970D0 (en) * | 2000-09-29 | 2000-11-15 | Smithkline Beecham Plc | Novel pharmaceutical |
| AU2002248464A1 (en) | 2001-02-21 | 2002-09-12 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US6531461B1 (en) | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| US20020198203A1 (en) * | 2001-06-07 | 2002-12-26 | Wyeth | Combination of a PTPase inhibitor and a thiazolidinedione agent |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| MXPA05004743A (es) | 2002-11-08 | 2005-08-03 | Hoffmann La Roche | Derivados 4-alcoxioxazol sustituidos como agonistas ppar. |
| US7264813B2 (en) | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
| CN102389427A (zh) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | 含有罗格列酮和盐酸西替利嗪的固体口服制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2195282C2 (ru) * | 1993-09-15 | 2002-12-27 | Санкио Компани Лимитед | Применение тиазолидиндионов для предотвращения или отдаления наступления инсулиннезависимого сахарного диабета (niddm) |
| HUP9802543A2 (hu) * | 1995-08-10 | 1999-07-28 | Warner-Lambert Company | Eljárás nem inzulinfüggő diabetes mellitusban szenvedő betegek esetében az adagolt exogén inzulin mennyiségének csökkentésére alkalmas tiazolindion-származékokat tartalmazó gyógyszerkészítmények előállítására |
| BR9610624A (pt) * | 1995-09-18 | 1999-03-16 | Ligand Pharm Inc | Tratamento de dmndi com agonistas de de rxr |
-
1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
-
1998
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 JP JP50375799A patent/JP2002504138A/ja not_active Ceased
- 1998-06-15 SK SK1793-99A patent/SK179399A3/sk unknown
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/pt not_active IP Right Cessation
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/ko not_active Ceased
- 1998-06-15 EA EA200000042A patent/EA004800B1/ru not_active IP Right Cessation
- 1998-06-15 ID IDW991627A patent/ID23951A/id unknown
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/hu unknown
- 1998-06-15 PL PL98343123A patent/PL343123A1/xx unknown
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 CN CNB988062232A patent/CN1133431C/zh not_active Expired - Fee Related
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/xx unknown
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Application Discontinuation
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 UA UA99126881A patent/UA70299C2/uk unknown
- 1998-06-15 IL IL13314398A patent/IL133143A0/xx unknown
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/xx active
- 1998-06-17 MA MA25122A patent/MA26511A1/fr unknown
- 1998-06-17 TW TW087109619A patent/TW587937B/zh not_active IP Right Cessation
- 1998-06-17 AR ARP980102886A patent/AR015894A1/es not_active Application Discontinuation
- 1998-06-17 AR ARP980102883A patent/AR012997A1/es not_active Application Discontinuation
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/xx unknown
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/es not_active Application Discontinuation
- 1998-06-18 UY UY25050A patent/UY25050A1/es unknown
- 1998-06-18 CO CO98034654A patent/CO4940454A1/es unknown
-
1999
- 1999-12-17 NO NO996265A patent/NO996265D0/no not_active Application Discontinuation
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
-
2000
- 2000-01-06 BG BG104059A patent/BG104059A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG104060A (en) | Diabetes treatment with thiazolyidindion and methformine | |
| ZA977783B (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
| BG104059A (en) | Diabetes treatment with rosiglytazone and insulin | |
| AU2373400A (en) | Shelf-stable formulation of glucagon-like peptide-1 | |
| WO2000057900A3 (en) | Factor for regulation of neurite growth | |
| EP0647133A4 (en) | COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY. | |
| AU2272097A (en) | Drug delivery compositions suitable for intravenous injection | |
| ZA94878B (en) | Prolonged delivery of peptides | |
| EP0767687A4 (en) | IMPLANTABLE PUMP FOR THE ADMINISTRATION OF A MEDICINE | |
| MY129220A (en) | "use of glp-1 analogs and derivatives administered peripherally in regulation of obesity" | |
| BG103740A (en) | Phytostyrene composition for the prevention of the alzheimer's disease | |
| WO2000016797A3 (en) | Use of glp-1 or analogs in treatment of stroke | |
| ZA967502B (en) | Medicament delivery device. | |
| ZA99104B (en) | Method for administering ASPB28-human insulin. | |
| CA2284482A1 (en) | Treatment of cardiomyopathy | |
| AU4714393A (en) | Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity | |
| BG104135A (en) | Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion | |
| ZA953537B (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
| EP0683668A4 (en) | PREPARATIONS AND METHODS FOR TRANSDERMAL DRUG ADMINISTRATION. | |
| BG104062A (en) | Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor | |
| BG104058A (en) | Diabetes treatment with thiazolydindion and sulphonylurea | |
| BG104139A (en) | Diabetes treatment with thizolidindion and sulphonylurea | |
| WO1999053064A3 (en) | Methods of delivering glp-1 | |
| AU8019898A (en) | Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome | |
| IL143088A0 (en) | A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method |